Sequenom, Inc.
SQNM, a life sciences company providing innovative diagnostic
testing and genetic analysis solutions, and CombiMatrix Corporation CBMX, a molecular diagnostics laboratory performing DNA-based testing
services for developmental disorders and cancer, today jointly announced that
the Sequenom Center for Molecular Medicine LLC (Sequenom CMM) and CombiMatrix
have entered into a collaboration agreement to market chromosomal microarray
analysis (CMA) testing services to broaden and confirm the results of
noninvasive, prenatal testing (NIPT) to physicians and their patients.
Under the agreement, the two laboratories will collaboratively use their
respective marketing channels and sales forces to promote the use of NIPT and
CMA and work together to provide technical training to physicians and
counseling, education and support services to physicians and their patients.
The two companies plan to provide, when clinically appropriate, a
comprehensive test result report for ordering physicians.
Sequenom is a global leader in the NIPT market, and Sequenom CMM, its wholly
owned subsidiary laboratory, developed the MaterniT21^TM PLUS
laboratory-developed test (LDT), a widely-ordered, noninvasive prenatal
testing service for fetal chromosomal abnormalities. CombiMatrix is one of the
few independent laboratories that specialize in CMA, the primary genetic test
to evaluate newborns with birth defects that is now being more widely used for
prenatal testing.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in